BNC Korea Co., Ltd. (256840.KQ)
KRW 4160.0
(-1.42%)
KRW 4160.0
(-1.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.94 Billion KRW | -48.27% |
| 2022 | 42.42 Billion KRW | -54.79% |
| 2021 | 93.83 Billion KRW | 206.36% |
| 2020 | 30.62 Billion KRW | 25.64% |
| 2019 | 24.37 Billion KRW | 24.28% |
| 2018 | 19.61 Billion KRW | 1147.18% |
| 2017 | 1.57 Billion KRW | -10.01% |
| 2016 | 1.74 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 27.15 Billion KRW | 32.76% |
| 2024 Q1 | 20.45 Billion KRW | -6.78% |
| 2023 Q1 | 38.51 Billion KRW | -9.21% |
| 2023 Q4 | 21.94 Billion KRW | 5.03% |
| 2023 Q3 | 20.89 Billion KRW | -3.9% |
| 2023 Q2 | 21.74 Billion KRW | -43.55% |
| 2023 FY | 21.94 Billion KRW | -48.27% |
| 2022 Q4 | 42.42 Billion KRW | -4.56% |
| 2022 Q2 | 32.14 Billion KRW | -56.58% |
| 2022 Q1 | 74.03 Billion KRW | -21.11% |
| 2022 Q3 | 44.44 Billion KRW | 38.29% |
| 2021 Q4 | 93.83 Billion KRW | -6.24% |
| 2021 Q3 | 100.07 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | 58.747% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | 45.176% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 91.718% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 94.612% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 91.667% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -29.713% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -0.143% |
| Boditech Med Inc. | 30.48 Billion KRW | 28.011% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 67.643% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -146.063% |
| Huons Co., Ltd. | 206.87 Billion KRW | 89.392% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | 42.538% |